Tacrolimus is indicated for the prevention and treatment of organ transplant rejection, including kidney, liver, and heart transplantation. It acts as a potent calcineurin inhibitor, suppressing T-cell activation and reducing immune-mediated graft damage. Its key advantage is strong and targeted immunosuppression, which significantly lowers the risk of acute rejection and improves long-term graft survival. Tacrolimus is a cornerstone therapy in modern transplant medicine and is often used as part of combination regimens with other immunosuppressants. Oral capsule formulation allows precise dose titration based on therapeutic drug monitoring, ensuring optimal balance between efficacy and safety. Its predictable clinical effect and extensive experience in use make it a reliable and essential option in transplant patient management.